6,901 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Purchased by Aquatic Capital Management LLC

Aquatic Capital Management LLC purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,901 shares of the company's stock, valued at approximately $1,081,000.

A number of other large investors also recently modified their holdings of KRYS. FMR LLC increased its holdings in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after acquiring an additional 21,133 shares during the period. Vanguard Group Inc. increased its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC raised its position in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after buying an additional 6,600 shares in the last quarter. Hood River Capital Management LLC boosted its stake in Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after buying an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Krystal Biotech by 16.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after buying an additional 71,200 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on KRYS shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. HC Wainwright upped their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Finally, Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $222.71.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $21.78 during trading on Tuesday, hitting $140.52. 565,397 shares of the company's stock traded hands, compared to its average volume of 295,949. The stock has a fifty day moving average of $174.63 and a two-hundred day moving average of $171.10. Krystal Biotech, Inc. has a 12-month low of $137.57 and a 12-month high of $219.34. The firm has a market cap of $4.06 billion, a P/E ratio of 46.76 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.35 by ($0.15). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).